The Tina Trial: A Phase III randomised placebo-controlled trial of mirtazapine as a pharmacotherapy for methamphetamine “Ice” dependence
May 2021
Staff:
Associate Professor Rebecca McKetin
Scientia Professor Louisa Degenhardt
Professor Michael Farrell
Ms Samantha Colledge
Other investigators:
Professor Gregory Dore, Kirby Institute UNSW
Professor Steven Shoptaw, University of California Los Angeles (UCLA)
Associate Professor Peter Kelly, University of Wollongong
Dr Alyna Turner, Deakin University
Dr Philip Clare, University of Sydney
Dr Shalini Arunogiri, Monash University
Professor Michael Berk, Deakin University
Associate Professor Olivia Dean, Deakin University
Dr Barbara Sinclair, Illawarra Shoalhaven Local Health District
David Reid, Illawarra Shoalhaven Local Health District
Dr Jeremy Hayllar, Metro North Hospital and Health Service
Dr David Goodman, University of California Los Angeles (UCLA)
Dr Michael Christmass, Mental Health Commission, WA
Juanita Koeijers, National Mental Health Consumer and Carer Forum
Project description:
Crystalline methamphetamine (“ice”) is a growing concern in Australia. There are no approved medications that can be used to treat dependence on this drug. This clinical trial will examine whether mirtazapine, a newly identified treatment agent for methamphetamine use, can be used safely and effectively in routine clinical care to manage methamphetamine dependence in Australia.
Read more here.
